Natália Rangel Palmier1, Adriana Franco Paes Leme2, Tatiane De Rossi2, Guilherme Pimentel Telles3, Karina Morais-Faria4, Luiz Paulo Kowalski5, Gustavo Nader Marta6,7, Thaís Bianca Brandão4,8, Praveen R Arany9, César Augusto Migliorati10, Alan Roger Santos-Silva1, Ana Carolina Prado-Ribeiro11. 1. Oral Diagnosis Department, Piracicaba Dental School, UNICAMP, Campinas, Brazil. 2. Brazilian Biosciences National Laboratory, LNBio, CNPEM, Campinas, Brazil. 3. Instituto de Computação, University of Campinas (UNICAMP), Campinas, Brazil. 4. Dental Oncology Service, Instituto do Câncer do Estado de São Paulo, ICESP-FMUSP, São Paulo, Brazil. 5. Central Institute, Hospital das Clínicas of the University of São Paulo Medical School (FMUSP), São Paulo, Brazil. 6. Department of Radiation Oncology, Hospital Sírio-Libanês, Sao Paulo, Brazil. 7. Department of Radiology and Oncology, Division of Radiation Oncology, Instituto do Câncer do Estado de São Paulo, ICESP-FMUSP, Sao Paulo, Brazil. 8. Oral Medicine Department, Hospital Sírio-Libanês, Sao Paulo, Brazil. 9. Oral Biology and Biomedical Engineering, University at Buffalo, Buffalo, NY, USA. 10. College of Dentistry, University of Florida, Gainesville, FL, USA. 11. Dental Oncology Service, Instituto do Câncer do Estado de São Paulo, ICESP-FMUSP, São Paulo, Brazil. carol_pr@yahoo.com.br.
Abstract
AIMS: Evaluate the abundance of the selected targets, alpha-1-antitrypsin (A1AT) and macrophage migration inhibitory factor (MIF), and correlate these findings with the risk of developing severe oral mucositis (OM). MATERIALS AND METHODS: Head and neck squamous cell carcinoma (HNSCC) patients submitted to radiotherapy (RT) or chemoradiotherapy (CRT) were assessed. OM grade and pain were evaluated daily during treatment. Two protein targets, A1AT and MIF, were evaluated, using selected reaction monitoring-mass spectrometry (SRM-MS), in whole saliva, collected prior to oncologic treatment. The results obtained from the targeted proteomic analysis were correlated with OM clinical outcomes. RESULTS: A total of 27 patients were included, of whom 21 (77.8%) had locally advanced disease (clinical stage III or IV). Most patients (70.4%) received CRT. OM grades 2 (40.8%) and 3 (33.3%) were the most prevalent during RT with a mean highest reported OM-related pain of 3.22 through the visual analogue scale (VAS). The abundance of A1AT and MIF correlated significantly with severe (grades 3 or 4, p < 0.02) compared with moderate-low (grades 1 or 2, p < 0.04) OM grade. CONCLUSIONS: There is a correlation between the abundance of salivary A1AT and MIF and oncologic treatment-induced OM. The correlation of MIF expression with severe OM appears to be compatible with its physiological pro-inflammatory role. These results open up great possibilities for the use of salivary MIF and A1AT levels as prognostic markers for effective therapeutic interventions, such as photobiomodulation therapy, patient-controlled analgesia, or personalized medicaments.
AIMS: Evaluate the abundance of the selected targets, alpha-1-antitrypsin (A1AT) and macrophage migration inhibitory factor (MIF), and correlate these findings with the risk of developing severe oral mucositis (OM). MATERIALS AND METHODS: Head and neck squamous cell carcinoma (HNSCC) patients submitted to radiotherapy (RT) or chemoradiotherapy (CRT) were assessed. OM grade and pain were evaluated daily during treatment. Two protein targets, A1AT and MIF, were evaluated, using selected reaction monitoring-mass spectrometry (SRM-MS), in whole saliva, collected prior to oncologic treatment. The results obtained from the targeted proteomic analysis were correlated with OM clinical outcomes. RESULTS: A total of 27 patients were included, of whom 21 (77.8%) had locally advanced disease (clinical stage III or IV). Most patients (70.4%) received CRT. OM grades 2 (40.8%) and 3 (33.3%) were the most prevalent during RT with a mean highest reported OM-related pain of 3.22 through the visual analogue scale (VAS). The abundance of A1AT and MIF correlated significantly with severe (grades 3 or 4, p < 0.02) compared with moderate-low (grades 1 or 2, p < 0.04) OM grade. CONCLUSIONS: There is a correlation between the abundance of salivary A1AT and MIF and oncologic treatment-induced OM. The correlation of MIF expression with severe OM appears to be compatible with its physiological pro-inflammatory role. These results open up great possibilities for the use of salivary MIF and A1AT levels as prognostic markers for effective therapeutic interventions, such as photobiomodulation therapy, patient-controlled analgesia, or personalized medicaments.
Entities:
Keywords:
Alpha 1-antitrypsin; Head and neck neoplasms; Macrophage migration inhibitory factors; Oral mucositis; Radiotherapy; Salivary proteins
Authors: Vincent Grégoire; Kian Ang; Wilfried Budach; Cai Grau; Marc Hamoir; Johannes A Langendijk; Anne Lee; Quynh-Thu Le; Philippe Maingon; Chris Nutting; Brian O'Sullivan; Sandro V Porceddu; Benoit Lengele Journal: Radiother Oncol Date: 2013-10-31 Impact factor: 6.280
Authors: Thaís Bianca Brandão; Karina Morais-Faria; Ana Carolina Prado Ribeiro; César Rivera; João Victor Salvajoli; Marcio Ajudarte Lopes; Joel B Epstein; Praveen R Arany; Gilberto de Castro; Cesar Augusto Migliorati; Alan Roger Santos-Silva Journal: Support Care Cancer Date: 2018-02-08 Impact factor: 3.603
Authors: Colin T Murphy; Thomas J Galloway; Elizabeth A Handorf; Brian L Egleston; Lora S Wang; Ranee Mehra; Douglas B Flieder; John A Ridge Journal: J Clin Oncol Date: 2015-11-30 Impact factor: 44.544
Authors: Stephen T Sonis; Sepehr Hashemi; Joel B Epstein; Raj G Nair; Judith E Raber-Durlacher Journal: Oral Oncol Date: 2016-02-03 Impact factor: 5.337
Authors: Héliton S Antunes; Luciene Fontes Schluckebier; Daniel Herchenhorn; Isabele A Small; Carlos M M Araújo; Celia Maria Pais Viégas; Mariana P Rampini; Elza M S Ferreira; Fernando L Dias; Vanessa Teich; Nelson Teich; Carlos G Ferreira Journal: Oral Oncol Date: 2015-11-11 Impact factor: 5.337